Bionano Genomics, Inc. revised revenue guidance for the third quarter ended September 30, 2023. Revenues for the third quarter of 2023 are expected to be in the range of $9.1 million to $9.3 million, an estimated increase of 26% to 29% compared to the third quarter of 2022, which would be at the higher end of revenue guidance of $8.8 million to $9.2 million provided in August 2023.
Market Closed -
Other stock markets
|
Pre-market 13:55:49 | |||
0.92 USD | -3.82% | 0.975 | +5.98% |
05-08 | Transcript : Bionano Genomics, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
05-08 | Bionano Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-51.32% | 61.51M | |
+8.07% | 219B | |
+7.87% | 185B | |
+12.75% | 135B | |
+25.79% | 107B | |
+11.59% | 51.28B | |
+4.88% | 51.01B | |
+2.71% | 41.85B | |
+4.90% | 37.02B | |
+23.75% | 31.27B |
- Stock Market
- Equities
- BNGO Stock
- News Bionano Genomics, Inc.
- Bionano Genomics, Inc. Revises Revenue Guidance for the Third Quarter Ended September 30, 2023